Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Chronic kidney disease

Association between ESA use and stroke in patients with CKD

Nature Reviews Nephrology volume 7, pages 365–366 (2011)Cite this article

Subjects

In response to data from trials showing an increase in clinical events with the use of erythropoiesis-stimulating agents (ESAs), Seliger et al. carried out an observational case–control study and have found that high doses of ESAs are associated with an increased risk of stroke.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Patient selection process from the VHA cohort in the Seliger et al. study.3

References

  1. Pfeffer, M. A. et al. for the TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019–2032 (2009).

    Article  Google Scholar 

  2. Singh, A. K. et al. for the CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085–2098 (2006).

    Article  CAS  Google Scholar 

  3. Seliger, S. L. et al. Erythropoiesis-stimulating agents increase the risk of acute stroke in patients with chronic kidney disease. Kidney Int. doi:10.1038/ki.2011.49.

    Article  CAS  Google Scholar 

  4. Besarab, A. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N. Engl. J. Med. 339, 584–590 (1998).

    Article  CAS  Google Scholar 

  5. Solomon, S. D. et al. for the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N. Engl. J. Med. 363, 1146–1155 (2010).

    Article  CAS  Google Scholar 

  6. Szczech, L. A. et al. Secondary analysis of the CHOIR trial epoetin-α dose and achieved hemoglobin outcomes. Kidney Int. 74, 791–798 (2008).

    Article  CAS  Google Scholar 

  7. Szczech, L. A. et al. A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. Kidney Int. 77, 239–246 (2010).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Room 7060, Durham, NC 27705, USA. szcze001@mc.duke.edu,

    Lynda Szczech

Authors
  1. Lynda Szczech
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

L. Szczech has worked as a consultant for Affymax, Akros Pharma, Amgen, FibroGen, GlaxoSmithKline, and Sandoz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Szczech, L. Association between ESA use and stroke in patients with CKD. Nat Rev Nephrol 7, 365–366 (2011). https://doi.org/10.1038/nrneph.2011.70

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2011.70

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing